Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm study of LZM012 in moderate-to-severe plaque psoriasis
CTR20252192Phase 3Completed
- Sponsor
- Lichen Biotech
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lzm012 in plaque psoriasis, sponsored by Lichen Biotech. Started Jun 2025; status: completed.
02
Drugs
lzm012
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20252192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252192.